CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease
Chemotherapy and radiation, then surgery, then a year of immunotherapy if the operation shows cancer was still there. This is the current curative-intent pathway.
CROSS gives 10-year OS of 38%; CheckMate 577 adds DFS 22.4 vs 11.0 months in the ~70% with residual disease after resection (OS HR 0.85, not significant). Patients with pathologic complete response do not receive nivolumab. SANO offers surveillance instead of surgery for clinical complete responders.
Pages like this
not linked directly; found by shared links- IdeaOrgan preservation as the default after complete response in oesophageal cancer
Shares Clinical complete response (cCR), SANO, CROSS, Oesophageal cancer.
- TermOesophagectomy
Shares SANO, CROSS, Oesophageal cancer.
- PairingNeoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer
Shares Clinical complete response (cCR), Neoadjuvant / adjuvant / perioperative, Nivolumab.
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Paclitaxel / nab-paclitaxel, Carboplatin.
- PersonYuko Kitagawa
Shares CROSS, Oesophageal cancer.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Paclitaxel / nab-paclitaxel, Carboplatin.
- IdeaPooled international procurement of essential adult cancer medicines
Shares Paclitaxel / nab-paclitaxel, Carboplatin.
- IdeaChoose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint
Shares Paclitaxel / nab-paclitaxel, Carboplatin.